A combination of chlorzoxazone and folic acid improves recognition memory, anxiety and depression in SCA3-84Q mice
Human Molecular Genetics · 2024
DOI: 10.1093/hmg/ddae079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2024. Verfasst von Ksenia S Marinina und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Neurodegeneration, Peter the Great St. Petersburg Polytechnic University, 29 Polytechnicheskaya str., St. Petersburg 195251, …. Hauptthemen laut MEDLINE: Anxiety, Depression, Folic Acid, Mice, Transgenic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Russian Science Foundation, RSF, NIH.
Themen: Depression
Abstract (Originalsprache)
Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is reported to be the most common type of autosomal dominant cerebellar ataxia (ADCA). SCA3 patients suffer from a progressive decline in motor coordination and other disease-associated symptoms. Moreover, recent studies have reported that SCA3 patients also exhibit symptoms of cerebellar cognitive affective syndrome (CCAS). We previously observed signs of CCAS in mouse model of SCA3. Particularly, SCA3-84Q mice suffer from anxiety, recognition memory decline, and also exhibit signs of low mood and aversion to activity. Here we studied the effect of long-term injections of SK channels activator chlorzoxazone (CHZ) together and separately with the folic acid (FA) on the cerebellar Purkinje cell (PC) firing and histology, and also on the motor and cognitive functions as well as mood alterations in SCA3-84Q hemizygous transgenic mice. We realized that both CHZ and CHZ-FA combination had similar positive effect on pure cerebellum impairments including PC firing precision, PC histology, and motor performance in SCA3-84Q mice. However, only the CHZ-FA combination, but not CHZ, had significantly ameliorated the signs of anxiety and depression, and also noticeably improved recognition memory in SCA3-84Q mice. Our results suggest that the combination therapy for both ataxia and non-motor symptoms is required for the complex treatment of ADCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Neurodegeneration, Peter the Great St. Petersburg Polytechnic University, 29 Polytechnicheskaya str., St. Petersburg 195251, Russia.
- Department of Physiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9040, United States.
ORCID-Profile: Polina A Egorova
Förderung
- Russian Science Foundation
- RSF
- NIH
- NIH HHS
- NIA NIH HHS
- National Institutes of Health
Zitieren
APA
Marinina, K. S., Bezprozvanny, I. B., & Egorova, P. A. (2024). A combination of chlorzoxazone and folic acid improves recognition memory, anxiety and depression in SCA3-84Q mice. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddae079
Vancouver
Marinina KS, Bezprozvanny IB, Egorova PA. A combination of chlorzoxazone and folic acid improves recognition memory, anxiety and depression in SCA3-84Q mice. Human Molecular Genetics. 2024. doi:10.1093/hmg/ddae079
BibTeX
@article{Marinina2024,
author = {Marinina, Ksenia S and Bezprozvanny, Ilya B and Egorova, Polina A},
title = {A combination of chlorzoxazone and folic acid improves recognition memory, anxiety and depression in SCA3-84Q mice},
journal = {Human Molecular Genetics},
year = {2024},
doi = {10.1093/hmg/ddae079}
}
EUVIMED